Letter to the Editor

Letters to the Editor will be published, if suitable, as space permits. They should not exceed 1000 words (typed double-spaced) in length and may be subject to editing or abridgment.

Use of Protoporphyrins to Evaluate Heme Oxygenase Problematical

To the Editor:

In the recent report by Vera et al1 with an associated editorial commentary by N.G. Abraham2 cobalt protoporphyrin (CoPP) is used as an inducer of heme oxygenase-1 to demonstrate that heme oxygenase-1 prevents angiotensin II hypertension. The possibility of CoPP interactions with a variety of other heme-containing proteins linked directly and indirectly to blood pressure, eg, soluble guanylyl cyclase (sGC) and cytochrome P450,3,4 should also be considered in interpreting the results. CoPP IX substitution and CoPP III have both been reported to activate purified sGC.5,6 The authors do not report the type or source of CoPP used in their studies. The effect of specific inhibitors of sGC, eg, 1H-(1,2,4)oxadiazolo [4,3-alpha]quinoxalin-1-one, on the response to CoPP infusions may help to address the role of sGC. However, if the effect of heme oxygenase-1 is partially mediated by activation of sGC by carbon monoxide, specific inhibitors of sGC may also prevent protection from angiotensin II hypertension by heme oxygenase-1.

Disclosures

None.

Robert S. Danziger
Department of Medicine
University of Illinois at Chicago

Use of Protoporphyrins to Evaluate Heme Oxygenase Problematical
Robert S. Danziger

Hypertension. 2009;53:e15; originally published online December 1, 2008;
doi: 10.1161/HYPERTENSIONAHA.108.125427
Hypertension is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2008 American Heart Association, Inc. All rights reserved.
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the
World Wide Web at:
http://hyper.ahajournals.org/content/53/2/e15

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Hypertension can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Hypertension is online at:
http://hyper.ahajournals.org/subscriptions/